Shoichiro Ohtani

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani et al. · New England Journal of Medicine · 2017 · 1.9K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 729 citations · Full text

Medicine, Oncology, Pharmacology +17

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

Eric P. Winer, Oleg Lipatov, Seock‐Ah Im et al. · The Lancet Oncology · 2021 · 493 citations

Medicine, Oncology, Pharmacology +14

A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients

Yasuhiro Fujiwara, Hirofumi Mukai, Toshiaki Saeki et al. · British Journal of Cancer · 2019 · 130 citations · Full text

Pharmacy, Oncology, Pharmacology +17